Non-Small Cell Lung Cancer (NSCLC) Clinical Trials

Find Non-Small Cell Lung Cancer (NSCLC) Clinical Trials Near You

Characterization of Multi-Omics Landscapes in Long-Term Survival Following Immunotherapy and Development of an AI Pathological Prediction Model for Long-Term Survival Based on H&E-Stained Images in Advanced Non-Small Cell Lung Cancer

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to establish a long-term survival (LTS) versus short-term survival (STS) real-world cohort, to systematically characterize the multi-omics landscapes, and to develop and validate an artificial intelligence (AI) pathological prediction model based on routine H\&E-stained images for predicting immune microenvironment features and long-term survival outcomes following immunotherapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with pathologically confirmed advanced or locally advanced non-small cell lung cancer (NSCLC).

• Patients derived from real-world data of multiple centers (including Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital of Shanxi, Chinese Academy of Medical Sciences \[Shanxi Cancer Hospital\]; and other participating centers) or from completed phase III clinical trials (e.g., Choice-01, Rationale-307, Rationale-304).

• Patients who received first-line or later-line immune checkpoint inhibitor (ICI) monotherapy or ICI-based combination therapy.

• Patients with complete clinical information and available follow-up data.

Locations
Other Locations
China
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING
Beijing
Contact Information
Primary
Jie Wang, MD,PhD
zlhuxi@163.com
8610-87788029
Backup
Jie Zhao, MD
zhaojie_12@163.com
17801204737
Time Frame
Start Date: 2026-05-01
Estimated Completion Date: 2030-05-01
Participants
Target number of participants: 600
Treatments
Long-term survival (LTS) group
patients with overall survival of more than 5 years after initial immunotherapy
Short-term survival (STS) group
patients with overall survival of less than 1 year after initial immunotherapy
Sponsors
Leads: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

This content was sourced from clinicaltrials.gov